Speaker

Diana Alcantara-Payawal, MD, DTMH, LIM, FPCP, FPSG, FPSDE,

Professor II

Chair, Department of Internal Medicine

Fatima University Medical Center

Chair

Committee of Hepatology

Cardinal Santos Medical Center

Tan Swee Jin, PhD, PMP
Senior Manager, Scientific Affairs, Sysmex Asia Pacific

Lecture Abstract

Liver fibrosis is a progressive condition that develops due to chronic liver injury, often from infections (such as hepatitis B and hepatitis C), metabolic disorders (such as Metabolic dysfunction-associated fatty liver disease [MAFLD] and Metabolic dysfunction-associated steatotic liver disease [MASLD], or alcohol-related liver damage. In the Philippines, the burden of liver fibrosis is particularly high due to the country’s elevated rates of viral hepatitis, alcohol use, and the increasing prevalence of metabolic diseases such as obesity and diabetes. Liver fibrosis is a major precursor to cirrhosis and hepatocellular carcinoma (HCC), two of the leading causes of liver-related morbidity and mortality in the region.

In this upcoming webinar, Prof. Diana Payawal, a renowned expert in hepatology, will provide an in-depth review of current practices in liver fibrosis assessment in the Philippines. The session will highlight the key challenges healthcare professionals face in liver fibrosis assessment and explore future outlook and strategies for improving liver disease outcomes with non-invasive biomarkers.